Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 2 1

Status

Withdrawn 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other 2Gastrointestinal 2Head & Neck 1

Conditions

Opioid-Related Disorders 1Opioid-Induced Constipation 1Neoplasms 1Constipation 1

Interventions

Exercise 28Metformin 24Surveys and Questionnaires 19Radiotherapy 14Methods 14Early Intervention, Educational 13Counseling 13Educational Status 12naloxegol 10Standard of Care 10Tirzepatide 9Nutrition Assessment 9Diet Therapy 9Cisplatin 9Resistance Training 8Psychiatric Rehabilitation 8Diet 8Therapeutics 7Interviews as Topic 7alvimopan 6Liraglutide 6Fibroblast Growth Factor 7 6Caloric Restriction 6semaglutide 5Radiation 5Low-Level Light Therapy 5Injections 5Exenatide 5Diet, Mediterranean 5Dexamethasone 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
methylnaltrexone × Other × Clear all
NCT00858754 2019-11-29

Study Evaluating Safety & Efficacy of Subcutaneous Methylnaltrexone on Opioid-Induced Constipation in Cancer Subjects

Bausch Health Americas, Inc.

Phase 4 Withdrawn
Other

Opioid-Induced Constipation

NCT01004393 2016-02-02

Methylnaltrexone for Opioid-induced Constipation in Cancer Patients

University of Vermont

Phase 2 Completed
12 enrolled 10 charts
Other

Constipation, Opioid-Related Disorders, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡